BUZZ-Alzamend rises after completing mid-stage brain lithium study
I'm PortAI, I can summarize articles.
Shares of clinical-stage drug developer Alzamend Neurorise 5.74% to $2.58 premarketCo says it finished the clinical portion of a mid-stage trial of AL001, a lithium-based therapy for Alzheimer’s and mood disordersStudy compared AL001 with marketed lithium carbonate to measure lithium levels in blood and brain using advanced imaging, co saysCo says goal is to deliver lithium more effectively to the brain while reducing systemic side effects and avoiding frequent blood testsALZN expects to release the main results in early 2026Up to last close, stock down ~77% YTD
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments